Accelerate Diagnostics (NASDAQ:AXDX) Issues Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Accelerate Diagnostics (NASDAQ:AXDX) issued its earnings results on Thursday. The medical research company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.13, Zacks reports. The company had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $3.00 million.

Accelerate Diagnostics Trading Down 6.2 %

Shares of AXDX stock traded down $0.07 on Friday, reaching $1.06. The company had a trading volume of 156,774 shares, compared to its average volume of 59,715. The company has a 50-day moving average of $1.16 and a 200-day moving average of $1.45. Accelerate Diagnostics has a 12 month low of $0.73 and a 12 month high of $2.09. The stock has a market cap of $26.55 million, a PE ratio of -0.37 and a beta of 0.55.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on AXDX shares. BTIG Research raised Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th. StockNews.com began coverage on Accelerate Diagnostics in a research report on Monday, March 17th. They issued a “hold” rating on the stock.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.